FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series D or later / Biotech startups that raised Series D or later in Asia

Biotech startups that raised Series D or later in Asia

Updated 16 Nov 2026

Reset
Biotech startups that raised Series D or later in Asia
One-time CSV
  • 98 funded companies, 74 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-d-plus~asia.csv98 rows × 18 columns
CompanyCityLast roundAmountDate
Drug FarmShanghaiSeries D$55.0M2026-07-13
VivolightNanshanquSeries E$13.9M2026-06-01
Full-Life TechnologiesShanghaiSeries D$109.0M2026-05-18
New Radiomedicine TechnologyChengduSeries E$145.4M2026-04-03
CORXEL PharmaceuticalsShanghaiSeries D$287.0M2026-01-22
MAXVAXShuangliuSeries D$27.4M2025-12-25
METiS PharmaceuticalsHangzhouSeries D$55.7M2025-08-04
IMPACT TherapeuticsNanjingSeries D$34.6M2024-11-15

8 rows of the CSV in 5 of its 18 columns.

98
Startups
$8.0B
Total raised
19
Funded in the last 12 months
$1.2B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

13 of 98
13 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Drug Farm Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. Artificial intelligence Shanghai, China Series D $55.0M 2026-07-13 $138.0M DT Capital Partners, South China Venture Capital, BVCF +1 101 to 250 2015
Vivolight Vivolight conducts medical research and develops intravascular interventional imaging technology. Biotech Nanshanqu, China Series E $13.9M 2026-06-01 $52.2M CAS Star, TusStar 51 to 100 2012
Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai, China Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
New Radiomedicine Technology New Radiomedicine Technology supplies medical isotopes in China. Biotech Chengdu, China Series E $145.4M 2026-04-03 $330.6M Chengdu Science and Technology Venture Capital 101 to 250 2016
CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Shanghai, China Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
MAXVAX MAXVAX develops and commercializes novel vaccines. Biotech Shuangliu, China Series D $27.4M 2025-12-25 $284.2M IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 251 to 500 2016
METiS Pharmaceuticals METiS Pharmaceuticals is an AI-driven drug formulation company. Artificial intelligence Hangzhou, China Series D $55.7M 2025-08-04 $391.7M Source Code Capital, Frees Fund, Luminous Ventures (former Lightspeed China Partners) 51 to 100 2020
IMPACT Therapeutics IMPACT Therapeutics develops similar drugs to treat cancer. Biotech Nanjing, China Series D $34.6M 2024-11-15 BioVenture, Lilly Asia Ventures, Decheng Capital +2 51 to 100 2009
Yidao Biotechnology Yidao Biotechnology researches and develops vaccines and biomedical products. Biotech Suzhou, China Series D $25.2M 2024-05-09 Qiming Venture Partners, Northern Light Venture Capital 2017
Atom Bioscience & Pharmaceutical Atom Bioscience is a clinical-stage biotechnology company. Biotech Suzhou, China Series D $82.1M 2023-10-16 Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 11 to 50 2012
Accellix Accellix provides an assay delivery platform. Biotech Jerusalem, Israel Series E $10.0M 2021-12-13 BroadOak Capital Partners 51 to 100 2013
DXY Unicorn DXY is an online healthcare community connecting doctors, consumers, and healthcare organizations. Biotech Hangzhou, China Series E $500.0M 2020-12-29 $682.0M Shunwei Capital, DCM Ventures, Legend Capital +1 101 to 250 2000
Nutrinia Nutrinia develops therapies for patients with intestinal failure. Biotech Ramat Gan, Israel Series D $30.0M 2016-08-18 OrbiMed, Pontifax, WuXi Healthcare Ventures +2 11 to 50 2003

Table 1. Biotech startups that raised Series D or later in Asia: the 13 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 98.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Shanghai, China Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
2 New Radiomedicine Technology New Radiomedicine Technology supplies medical isotopes in China. Biotech Chengdu, China Series E $145.4M 2026-04-03 $330.6M Chengdu Science and Technology Venture Capital 101 to 250 2016
3 Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai, China Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
4 Drug Farm Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. Artificial intelligence Shanghai, China Series D $55.0M 2026-07-13 $138.0M DT Capital Partners, South China Venture Capital, BVCF +1 101 to 250 2015
5 MAXVAX MAXVAX develops and commercializes novel vaccines. Biotech Shuangliu, China Series D $27.4M 2025-12-25 $284.2M IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 251 to 500 2016
6 Vivolight Vivolight conducts medical research and develops intravascular interventional imaging technology. Biotech Nanshanqu, China Series E $13.9M 2026-06-01 $52.2M CAS Star, TusStar 51 to 100 2012

Table 2. Biotech startups that raised Series D or later in Asia: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 IDG Capital Private equity firm Beijing, China 2 2% 1 MAXVAX
2 WuXi Healthcare Ventures Venture capital firm Cambridge, United States 2 2%
3 EFung Capital Private equity firm Shenzhen, China 2 2%
4 Qiming Venture Partners Venture capital firm Shanghai, China 2 2%
5 South China Venture Capital Private equity firm Shenzhen, China 1 1% 1 Drug Farm
6 YD Capital Private equity firm Prague, Czech Republic 1 1% 1 Drug Farm
7 BVCF Private equity firm Shanghai, China 1 1% 1 Drug Farm
8 DT Capital Partners Private equity firm Shanghai, China 1 1% 1 Drug Farm
9 CAS Star Startup incubator Xian, China 1 1% 1 Vivolight
10 TusStar Startup accelerator Beijing, China 1 1% 1 Vivolight
11 Summer Capital Private equity firm Hong Kong 1 1% 1 Full-Life Technologies
12 Sky9 Capital Venture capital firm 1 1% 1 Full-Life Technologies
13 Chengwei Capital Venture capital firm Shanghai, China 1 1% 1 Full-Life Technologies
14 Prosperity7 Ventures Venture capital firm Dhahran, Saudi Arabia 1 1% 1 Full-Life Technologies
15 Chengdu Science and Technology Venture Capital Venture capital firm Chengdu, China 1 1% 1 New Radiomedicine Technology

Table 3. Biotech startups that raised Series D or later in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 86 88% $7.2B
Software 8 8% $1.2B
Artificial intelligence 4 4% $529.7M
Hardware 3 3%
Cybersecurity 1 1%

Table 4. Biotech startups that raised Series D or later in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series D+ 98 100% $36.9M

Table 5. Biotech startups that raised Series D or later in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
China 74 76%
Israel 11 11%
Japan 4 4%
India 3 3%
South Korea 3 3%
Taiwan 2 2%
Singapore 1 1%

Table 6. Biotech startups that raised Series D or later in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 20 20%
Beijing 11 11%
Hangzhou 7 7%
Suzhou 6 6%
Tokyo 3 3%
Nanjing 3 3%
Shenzhen 2 2%
Wuhan 2 2%
Changzhou 2 2%
Guangzhou 2 2%
Minhang 2 2%
Caesarea 2 2%

Table 7. Biotech startups that raised Series D or later in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
September 2026 3 16% $208.7M
August 2026 1 5% $97.1M
July 2026 2 11% $91.9M
June 2026 2 11% $60.8M
May 2026 2 11% $116.9M
April 2026 1 5% $145.4M
March 2026 2 11% $46.0M
January 2026 2 11% $294.7M
December 2025 4 21% $137.5M

Table 8. Biotech startups that raised Series D or later in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 15 15% $1.1B
2025 12 12% $350.9M
2024 8 8% $212.7M
2023 10 10% $316.3M
2022 9 9% $261.4M
2021 14 14% $909.5M

Table 9. Biotech startups that raised Series D or later in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 3 3%
2015 to 2019 31 32%
2010 to 2014 34 35%
Before 2010 30 31%

Table 10. Biotech startups that raised Series D or later in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 5 5%
11 to 50 28 29%
51 to 100 17 18%
101 to 250 24 25%
251 to 500 8 8%
501 to 1,000 11 11%
1,001 to 5,000 2 2%
5,001 to 10,000 1 1%

Table 11. Biotech startups that raised Series D or later in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Asia whose last round is Series D or later are on the list?
98, in the file dated 16 November 2026. 19 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 98 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series D or later in Asia: 98 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Asia

Other sectors that raised Series D or later in Asia

Cite: FundingWatcher, 98 biotech companies in Asia whose most recent round is Series D or later, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-d-plus/asia/